Atlas Trials

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Clinical trial NCT07162051 · COMPLETED

Trial details

NCT number
NCT07162051
Sponsor
Xijing Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HR+/HER2- Early Breast Cancer
Start date
2023-03-03
Primary completion
2026-02-15
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.